erus BioSciences(CHRS) - 2024 Q4 - Annual Results

Financial Performance - Coherus BioSciences, Inc. will present preliminary unaudited net revenues for Q4 2024 and the fiscal year ended December 31, 2024 at the 42nd Annual J.P. Morgan Healthcare Conference[4] - The financial closing procedures for Q4 2024 are not yet complete, which may lead to significant changes in the preliminary unaudited results[5] Product Demand - Due to strong demand in Q4 2024 and into Q1 2025, all three presentations of UDENYCA are being temporarily allocated[6]